|
Selected Industry Projects
- Antihypertensive agents: amlopidine, ramipril - Phase 3 reports
- Anti-infectives: azithromycin, linezolid - Phase 3 reports, quality control
- Antiplatelet agent: clopidegrel - Phase 1 reports
- Antithrombotic: factor Xa inhibitor - Phase 1 reports
- Breast cancer: fulvestrant - Informed consent document
- Diabetes: troglitazone - Phase 3 reports
- Esophageal cancer: nimotuzumab - Protocol
- Global Innovate!! implementation of progressive business ideas
- Hormone replacement: norethindrone acetate/ethinyl estradial - Phase 3 reports
- Hypercholesterolemia: torcetrapib / atorvastatin - Phase 2 reports
- Leukemia: imatinib, nilotinib - Phase 2 report
- Neuropathic pain: gabapentin, pregabalin - Phase 3 reports, safety narratives
- Renal disease: mycophenolate sodium - Protocol
- Selective estrogen receptor modulator (SERM): lasofoxifene - Phase 2/3 reports
- Smoking cessation: varenicline - Phase 3 reports
|
Salerno Scientific
Deborah F. Salerno, PhD
1530 Northwood Street
Ann Arbor, MI 48103 - USA
Tel + (734) 662-1572
info@SalernoScientific.com
|
